{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:05:58Z","timestamp":1762459558811,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T00:00:00Z","timestamp":1513555200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s11011-017-0169-z","type":"journal-article","created":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T09:34:43Z","timestamp":1513589683000},"page":"981-986","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cardiovascular profile improvement during Natalizumab treatment"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2613-3090","authenticated-orcid":false,"given":"Marcello","family":"Moccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Albero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Sacc\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia Valeria","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Carotenuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,18]]},"reference":[{"issue":"5","key":"169_CR1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1212\/01.WNL.0000113750.11090.67","volume":"62","author":"V Brescia Morra","year":"2004","unstructured":"Brescia Morra V, Coppola G, Orefice G, De Michele G, Vacca G, Filla A et al (2004) Interferon-b treatment decreases cholesterol plasma levels in multiple sclerosis patients. Neurology 62(5):829\u2013830. \nhttps:\/\/doi.org\/10.1212\/01.WNL.0000113750.11090.67","journal-title":"Neurology"},{"issue":"4","key":"169_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/1755-5922.12126","volume":"33","author":"A Cerda","year":"2015","unstructured":"Cerda A, Rodrigues AC, Alves C, Dalla F, Genvigir V, Fajardo CM et al (2015) Modulation of adhesion molecules by cholesterol-lowering therapy in mononuclear cells from Hypercholesterolemic patients. Cardiovasc Ther 33(4):168\u2013176. \nhttps:\/\/doi.org\/10.1111\/1755-5922.12126","journal-title":"Cardiovasc Ther"},{"issue":"9936","key":"169_CR3","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","volume":"383","author":"J Chataway","year":"2014","unstructured":"Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, Anderson V, Bangham CRM, Clegg S, Nielsen C, Fox NC, Wilkie D, Nicholas JM, Calder VL, Greenwood J, Frost C, Nicholas R (2014) Eff ect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 383(9936):2213\u20132221. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(13)62242-4","journal-title":"Lancet"},{"issue":"4","key":"169_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s11011-009-9159-0","volume":"24","author":"G Hon","year":"2009","unstructured":"Hon G, Hassan M, van Rensburg S, Abel S, Erasmus R, Matsha T (2009) Membrane saturated fatty acids and disease progression in multiple sclerosis patients. Metab Brain Dis 24(4):561\u2013568. \nhttps:\/\/doi.org\/10.1007\/s11011-009-9159-0","journal-title":"Metab Brain Dis"},{"key":"169_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/srep43410","volume":"7","author":"W Jorissen","year":"2017","unstructured":"Jorissen W, Wouters E, Bogie JF, Vanmierlo T, Noben J, Sviridov D et al (2017) Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL. Sci Rep 7:43410. \nhttps:\/\/doi.org\/10.1038\/srep43410","journal-title":"Sci Rep"},{"issue":"2","key":"169_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp-2014-310051","volume":"87","author":"N Kappus","year":"2016","unstructured":"Kappus N, Weinstock-guttman B, Hagemeier J, Kennedy C, Melia R, Carl E et al (2016) Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 87(2):181\u2013187. \nhttps:\/\/doi.org\/10.1136\/jnnp-2014-310051","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"169_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/ane.12718","volume":"136","author":"R Lanzillo","year":"2017","unstructured":"Lanzillo R, Carotenuto A, Moccia M, Sacc\u00e0 F, Russo CV, Massarelli M, de Rosa A, Brescia Morra V (2017) A longitudinal real-life comparison study of natalizumab and fingolimod. Acta Neurol Scand 136(3):217\u2013222. \nhttps:\/\/doi.org\/10.1111\/ane.12718","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"169_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/1352458509358909","volume":"16","author":"R Lanzillo","year":"2010","unstructured":"Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V (2010) Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler 16(4):450\u2013454. \nhttps:\/\/doi.org\/10.1177\/1352458509358909","journal-title":"Mult Scler"},{"issue":"3","key":"169_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1177\/1352458514564485","volume":"21","author":"RA Marrie","year":"2015","unstructured":"Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter GA (2015) Systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler 21(3):318\u2013331. \nhttps:\/\/doi.org\/10.1177\/1352458514564485","journal-title":"Mult Scler"},{"issue":"4","key":"169_CR10","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00415-015-7666-y","volume":"262","author":"M Moccia","year":"2015","unstructured":"Moccia M, Lanzillo R, Costabile T, Russo C, Carotenuto A, Sasso G, Postiglione E, de Luca Picione C, Vastola M, Maniscalco GT, Palladino R, Brescia Morra V (2015a) Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study. J Neurol 262(4):961\u2013967. \nhttps:\/\/doi.org\/10.1007\/s00415-015-7666-y","journal-title":"J Neurol"},{"issue":"8","key":"169_CR11","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/ene.12720","volume":"22","author":"M Moccia","year":"2015","unstructured":"Moccia M, Lanzillo R, Palladino R, Maniscalco GT, De Rosa A, Russo C, Massarelli M, Carotenuto A, Postiglione E, Caporale O, Triassi M, Brescia Morra V (2015b) The Framingham cardiovascular risk score in multiple sclerosis. Eur J Neurol 22(8):1176\u20131183. \nhttps:\/\/doi.org\/10.1111\/ene.12720","journal-title":"Eur J Neurol"},{"issue":"1\u20132","key":"169_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jns.2015.08.1537","volume":"358","author":"L Novakova","year":"2015","unstructured":"Novakova L, Axelsson M, Malmestr\u00f6m C, Zetterberg H, Bj\u00f6rkhem I, Karrenbauer VD, Lycke J (2015) Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis. J Neurol Sci 358(1\u20132):201\u2013206. \nhttps:\/\/doi.org\/10.1016\/j.jns.2015.08.1537","journal-title":"J Neurol Sci"},{"issue":"4","key":"169_CR13","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s11011-015-9665-1","volume":"30","author":"A Penesova","year":"2015","unstructured":"Penesova A, Vlcek M, Imrich R, Vernerova L, Marko A, Meskova M, Grunnerova L, Turcani P, Jezova D, Kollar B (2015) Hyperinsulinemia in newly diagnosed patients with multiple sclerosis. Metab Brain Dis 30(4):895\u2013901. \nhttps:\/\/doi.org\/10.1007\/s11011-015-9665-1","journal-title":"Metab Brain Dis"},{"issue":"2","key":"169_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292\u2013302. \nhttps:\/\/doi.org\/10.1002\/ana.22366","journal-title":"Ann Neurol"},{"issue":"Issue 13, Part","key":"169_CR15","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1212\/01.wnl.0000306410.84794.4d","volume":"70","author":"CH Polman","year":"2008","unstructured":"Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, Panitch H, Richert JR, Petkau J, Schwid SR, Sormani MP, Thompson AJ, Weinshenker BG, Wolinsky JS (2008) Ethics of placebo-controlled clinical trials in multiple sclerosis. Neurology 70(Issue 13, Part 2):1134\u20131140. \nhttps:\/\/doi.org\/10.1212\/01.wnl.0000306410.84794.4d","journal-title":"Neurology"},{"key":"169_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.msard.2016.03.019","volume":"7","author":"AJ Solomon","year":"2016","unstructured":"Solomon AJ, Bernat JLA (2016) Review of the ethics of the use of placebo in clinical trials for relapsing-remitting multiple sclerosis therapeutics. Mult Scler Relat Disord 7:109\u2013112. \nhttps:\/\/doi.org\/10.1016\/j.msard.2016.03.019","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"169_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/1755-5922.12049","volume":"32","author":"Z Sternberg","year":"2014","unstructured":"Sternberg Z, Leung C, Sternberg D, Yu J, Hojnacki D (2014) Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis. Cardiovasc Ther 32(2):33\u201339. \nhttps:\/\/doi.org\/10.1111\/1755-5922.12049","journal-title":"Cardiovasc Ther"},{"issue":"13","key":"169_CR18","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1177\/1352458514533162","volume":"20","author":"P Tettey","year":"2014","unstructured":"Tettey P, Jr SS, Taylor B, Blizzard L, Ponsonby A, Dwyer T et al (2014) An adverse lipid profile is associated with disability and progression in disability, in people with MS. Mult Scler 20(13):1737\u20131744. \nhttps:\/\/doi.org\/10.1177\/1352458514533162","journal-title":"Mult Scler"},{"key":"169_CR19","doi-asserted-by":"crossref","unstructured":"Tettey P, Simpson S, Taylor B, Ponsonby A, Lucas R, Dwyer T et al (2017) An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event. J Neurol Neurosurg Psychiatry 88(5):395\u2013401","DOI":"10.1136\/jnnp-2016-315037"},{"issue":"2","key":"169_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1194\/jlr.M072751","volume":"58","author":"T Uher","year":"2017","unstructured":"Uher T, Fellows K, Horakova D, Zivadinov R, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, Bergsland N, Weinstock-Guttman B, Havrdova E, Ramanathan M (2017) Serum lipid profile changes predict neurodegeneration in interferon-B1a treated multiple sclerosis patients. J Lipid Res 58(2):403\u2013411. \nhttps:\/\/doi.org\/10.1194\/jlr.M072751","journal-title":"J Lipid Res"},{"issue":"11","key":"169_CR21","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/jnnp-2012-304740","volume":"84","author":"B Weinstock-Guttman","year":"2013","unstructured":"Weinstock-Guttman B, Zivadinov R, Horakova D, Havrdova E, Qu J, Shyh G, Lakota E, O'Connor K, Badgett D, Tama\u00f1o-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z, Ramanathan M (2013) Lipid profiles are associated with lesion formation over 24 months in interferon-\u03b2 treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry 84(11):1186\u20131191. \nhttps:\/\/doi.org\/10.1136\/jnnp-2012-304740","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"169_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.msard.2015.10.005","volume":"5","author":"S Zhornitsky","year":"2016","unstructured":"Zhornitsky S, Mckay KA, Metz LM, Teunissen CE (2016) Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. Mult Scler Relat Disord 5:53\u201365. \nhttps:\/\/doi.org\/10.1016\/j.msard.2015.10.005","journal-title":"Mult Scler Relat Disord"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11011-017-0169-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-017-0169-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-017-0169-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T02:08:09Z","timestamp":1526436489000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11011-017-0169-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,18]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["169"],"URL":"https:\/\/doi.org\/10.1007\/s11011-017-0169-z","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"type":"print","value":"0885-7490"},{"type":"electronic","value":"1573-7365"}],"subject":[],"published":{"date-parts":[[2017,12,18]]}}}